XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Equity (Unaudited) - USD ($)
$ in Thousands
Total
Additional Paid-in Capital
Accumulated Deficit
Accumulated other income
Noncontrolling interests
Series A
Common Stock
Series B
Common Stock
Balance at Jul. 31, 2020 $ 130,528 $ 129,136 $ (16,255) $ 3,762 $ 13,728 $ 8 $ 149
Balance (in Shares) at Jul. 31, 2020           787,163 15,028,536
Net loss (9,668) (9,611) (57)
Stock-based compensation 433 433
Stock-based compensation (in Shares)             41,082
Stock-based compensation to Board of Directors 286 286          
Stock-based compensation to Board of Directors (in Shares)             12,609
Shares issued - Securities Purchase Agreements 13,000 12,994         $ 6
Shares issued - Securities Purchase Agreements (in Shares)             567,437
Shares withheld for payroll taxes (146) (146)          
Shares withheld for payroll taxes (in Shares)             (6,294)
Stock options exercised 43 43
Stock options exercised (in Shares)           8,750
Capital contribution for noncontrolling interest 912 912
Foreign currency translation adjustment (1) (1)
Balance at Jan. 31, 2021 135,387 142,746 (25,866) 3,761 14,583 $ 8 $ 155
Balance (in Shares) at Jan. 31, 2021           787,163 15,652,120
Balance at Oct. 31, 2020 129,316 129,393 (17,701) 3,724 13,743 $ 8 $ 149
Balance (in Shares) at Oct. 31, 2020           787,163 15,044,547
Net loss (8,237) (8,165) (72)
Stock-based compensation 219 219
Stock-based compensation (in Shares)           33,821
Stock-based compensation to Board of Directors 286 286
Stock-based compensation to Board of Directors (in Shares)             12,609
Shares issued - Securities Purchase Agreements 13,000 12,994         $ 6
Shares issued - Securities Purchase Agreements (in Shares)             567,437
Shares withheld for payroll taxes (146) (146)
Shares withheld for payroll taxes (in Shares)             (6,294)
Capital contribution for noncontrolling interest 912 912
Foreign currency translation adjustment 37 37
Balance at Jan. 31, 2021 135,387 142,746 (25,866) 3,761 14,583 $ 8 $ 155
Balance (in Shares) at Jan. 31, 2021           787,163 15,652,120
Balance at Jul. 31, 2021 136,704 159,136 (40,799) 3,772 14,418 $ 8 $ 169
Balance (in Shares) at Jul. 31, 2021           787,163 16,936,864
Net loss (131,976) (114,345) (17,631)
Stock-based compensation 15,883 15,882 $ 1
Stock-based compensation (in Shares)             63,360
Acquisition of additional ownership interest in LipoMedix 8 (8)
Forfeiture of restricted stock (18,978) (18,969) $ (9)
Forfeiture of restricted stock (in Shares)           (908,497)
Common stock sold to investors 99,170 99,142 $ 28
Common stock sold to investors (in Shares)           2,833,425
Transaction costs incurred in connection with sale of common stock (6,228) (6,228)
Common stock sold to related party 4,997 4,996 $ 1
Common stock sold to related party (in Shares)           112,501
Shares withheld for payroll taxes (71) (71)  
Shares withheld for payroll taxes (in Shares)             (8,641)
Foreign currency translation adjustment 155 155
Balance at Jan. 31, 2022 99,656 253,896 (155,144) 3,927 (3,221) $ 8 $ 190
Balance (in Shares) at Jan. 31, 2022           787,163 19,029,012
Balance at Oct. 31, 2021 113,062 264,867 (152,823) 3,781 (2,969) $ 8 $ 198
Balance (in Shares) at Oct. 31, 2021           787,163 19,882,219
Net loss (2,565) (2,321) (244)
Stock-based compensation 8,032 8,031 $ 1
Stock-based compensation (in Shares)             63,360
Acquisition of additional ownership interest in LipoMedix 8 (8)
Forfeiture of restricted stock (18,978) (18,969) $ (9)
Forfeiture of restricted stock (in Shares)             (908,497)
Shares withheld for payroll taxes (41) (41)
Shares withheld for payroll taxes (in Shares)           (8,070)
Foreign currency translation adjustment 146 146
Balance at Jan. 31, 2022 $ 99,656 $ 253,896 $ (155,144) $ 3,927 $ (3,221) $ 8 $ 190
Balance (in Shares) at Jan. 31, 2022           787,163 19,029,012